Transparency Market Research in its new report titled, “Alzheimer’s Disease Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the Alzheimer’s disease biomarkers market. The TMR report anticipates that the technical advancements in diagnostic tests and tools for Alzheimer’s disease will propel the Alzheimer’s disease biomarkers market during the forecast period i.e, 2018-2026. However, accessibility of these tests and tools and estimated high cost of procedures are likely to hamper the market during the forecast period, says the report.
According to the report, Alzheimer’s disease can be diagnosed using specific biomarkers such as peptides and genes. These biomarkers play an important role in predictive and confirmatory diagnosis of Alzheimer’s disease. The TMR report has segmented the global Alzheimer’s disease biomarkers market based on type of biomarker, detection technique, end-user, and region. Based on the type of biomarker, the market is classified into peptide-based, gene-based, imaging biomarkers, and others. The peptide-based segment is categorized into beta amyloid-based, tau protein-based, and others. The gene-based segment can be divided into apolipoprotein E-based, amyloid precursor protein & presenilin-based, and others. Among these, gene-based biomarkers are likely to be more accurate. Increase in demand for molecular diagnostics such as PCR is projected to spur adoption of these biomarkers. In terms of detection technique, the global Alzheimer’s disease biomarkers market is segmented into polymerase chain reaction (PCR), enzyme linked immunoassay (ELISA), and radiology imaging such as CT, MRI, and PET scan. Major end-users of Alzheimer’s disease biomarkers are hospitals & clinics, independent diagnostic laboratories, and others.
From a regional perspective, the global Alzheimer’s disease biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. High adoption of technically advanced diagnostic tools and better reimbursement support in the U.S. are projected to boost the Alzheimer’s disease biomarkers market in North America during the forecast period. A report published by Alzheimer’s disease International stated that an estimated 10.5 million people in Europe and 22.9 million in Asia Pacific were reported to have Alzheimer’s disease in 2015. High prevalence of Alzheimer’s disease in these regions is anticipated to propel the Alzheimer’s disease biomarkers market in Europe and Asia Pacific during the forecast period. However, limited access, lack of awareness, and estimated high cost of diagnostic procedures are expected to restrain the market in Asia Pacific.
Some of the prominent players operating in the global Alzheimer’s disease biomarkers market are profiled in this report and these include NanoSomix, Inc., Fujirebio, Imagilys SPRL, Merck KGaA, Enzo Life Sciences, Inc., Cell Signaling Technology, Inc., QIAGEN, 23andMe, Inc., AnaSpec, Inc., and Thermo Fisher Scientific, and others.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]